Demeclocycline HCl
产品说明书
 |
同义名 : | 地美环素 ;Demeclocycline (hydrochloride); Demethyltetracycline; Demethylchlortetracycline; Demeclocycline HCl |
| CAS号 : | 64-73-3 | |
| 货号 : | A115695 | |
| 分子式 : | C21H22Cl2N2O8 | |
| 纯度 : | 90% +(>900ug/mg) | |
| 分子量 : | 501.31 | |
| MDL号 : | MFCD00082371 | |
| 存储条件： |
Pure form Sealed in dry, store in freezer, under -20°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Demeclocycline HCl is a tetracycline antibiotic; is an antibiotic in the treatment of Lyme disease, acne, and bronchitis. Demeclocycline caused a dose-dependent decrease in IOP (intraocular pressure). The maximum IOP decrease of approximately 12 mm Hg occurred 5 days after intravitreal administration of 0.5 mg, with the effect persisting for over a week. Demeclocycline did not alter tonographically measured aqueous humor outflow facility or episcleral venous pressure. Intravitreal demeclocycline similarly lowered IOP in cats, with the duration of effect lasting up to 20 days[3]. Demeclocycline appears therefore to be an effective maintenance treatment of SIADH (inappropriate secretion of antidiuretic hormone), and the azotaemia that occurs is reversible and probably dose dependent[4]. Perioperative administration of demeclocycline reliably inhibits the effects of increased VP (vasopressin) secretion commonly seen in patients undergoing CABG (coronary artery bypass grafting) procedures[5]. Moreover, demeclocycline hydrochloride (1,200 mg/day) induced production of hypotonic urine and corrected hyponatremia despite large fluid intakes[6]. Demeclocycline (900 mg/day) can at least partially inhibit the action of ADH (inappropriate antidiuretic hormone) in the setting of tumor-induced ADH secretion, with the production of a reversible, partial nephrogenic diabetes insipidus, and with few or no side effects. Demeclocycline may be useful in the treatment of chronic inappropriate ADH secretion[7]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT02099240 | Osteomyelitis | Early Phase 1 | Recruiting | September 2019 | United States, Kentucky ... 展开 >> University of Louisville Recruiting Louisville, Kentucky, United States, 40202 Contact: Julio A Ramirez, MD 502-852-1148 jarami01@louisville.edu Contact: David Seligson, MD 502-852-0923 d0seli01@louisville.edu Sub-Investigator: Forest Arnold, DO Sub-Investigator: Timothy Wiemkwn, PhD Sub-Investigator: Robert Kelley, PhD Sub-Investigator: James Summersgill, PhD Sub-Investigator: Ruth Carrico, PhD Sub-Investigator: Julie Harting, PharmD Sub-Investigator: Paula Peyrani, MD Principal Investigator: David Seligson, MD Sub-Investigator: Craig Roberts, MD Principal Investigator: Julio Ramirez, MD 收起 << |
| NCT02771535 | Unipolar Depression | Not Applicable | Completed | - | Germany ... 展开 >> University Medical Center Hamburg Eppendorf Hamburg, Germany, 20246 收起 << |
| NCT03268434 | Unipolar Depression | Not Applicable | Recruiting | September 2019 | Germany ... 展开 >> Asklepios Klinik Nord-Ochsenzoll Recruiting Hamburg, Germany, 22419 Contact: Marion Hagemann-Goebel, Dr. 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.99mL 0.40mL 0.20mL |
9.97mL 1.99mL 1.00mL |
19.95mL 3.99mL 1.99mL |
| 参考文献 |
|---|